利奈唑胺治疗耐多药结核病的现状及认识

摘要

目前,耐多药结核病(MDR-TB)和泛耐药结核病(XDR-TB)仍是严重危害人类健康的全球公共卫生问题之一,但因治疗尚缺乏有效的药物,给临床治疗带来较大的困难.利奈唑胺(linezolid,LZD)是一种人工合成的噁唑烷酮类抗生素,对结核分枝杆菌(MTB)有杀菌作用,其临床疗效已得到一系列临床研究证实.但在使用过程中,对该药的认识还存在一定的困惑.作者就LZD治疗耐多药结核病的现状、作用特点和使用过程中面临的耐药性、安全性、使用剂量等问题做一综述,旨在提高医务人员对LZD治疗耐多药结核病的认识.%Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB are still a serious global public health problems.The treatment of drug-resistant TB is very difficult because of lack of effective drugs.Linezolid is a synthetic oxazolidinone antibacterial drugs and has bactericidal effect on Mycobacterium tuberculosis.Its clinical efficacy has been confirmed by a series of clinical studies.However, in the course of using linezolid, there is still some confusion.We reviewed treatment of drug-resistant tuberculosis using linezolid including the drug resistance, safety, dosage and so on, in order to elucidate the effect of linezolid in the treatment of MDR-TB.